Theragnostic 64Cu/67Cu Radioisotopes Production With RFT-30 Cyclotron

Lee, Jun Young; Chae, Jung Ho; Hur, Min Goo; Yang, Seung Dae; Kong, Young Bae; Lee, Jong‐Chul; Ju, Jin Sik; Choi, Pyeong Seok; Park, Jeong Hoon

doi:10.3389/fmed.2022.889640

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radionuclide content of the produced [ 67 Cu]CuCl 2 solution is characterized by gamma spectroscopy, quantifying a RNP of 99.5%, with radionuclide impurities consisting of 64 Cu (0.3%), 61 Cu (0.03%), 67 Ga (0.1%) and 66 Ga (0.05%), comparable to previously published results [22]. It is worthwhile mentioning that the 67 Ga content is estimated from the detected 66 Ga activity, since both 67 Cu and 67 Ga share the same gamma lines only with different intensities, making it nearly impossible to directly quantify the gallium-67 impurities.…”

Section: [ 67 Cu]cucl 2 Productionsupporting

confidence: 84%

Production of Medical Radionuclides in the Center for Radiopharmaceutical Tumor Research—A Status Report

Kreller,

Brühlmann,

Knieß

et al. 2024

Instruments

View full text Add to dashboard Cite

A new Center for Radiopharmaceutical Cancer Research was established at the Helmholtz-Zentrum Dresden-Rossendorf in 2017 to centralize radionuclide and radiopharmaceutical production, as well as enable chemical and biochemical research. Routine production of several radionuclides was put into operation in recent years. We report on the production methods of radiopharmaceutical radionuclides, in particular 11C, 18F, and radio metals like 61Cu, 64Cu, 67Cu, 67Ga, 131Ba, and 133La that are used regularly. In the discussion, we report typical irradiation parameters and achieved saturation yields.

show abstract

Section: [ 67 Cu]cucl 2 Productionsupporting

confidence: 84%

Production of Medical Radionuclides in the Center for Radiopharmaceutical Tumor Research—A Status Report

Kreller,

Brühlmann,

Knieß

et al. 2024

Instruments

View full text Add to dashboard Cite

show abstract

“…Later on, Jamriska et al [ 36 ] and Kastleiner et al [ 27 ] showed consistent results. With a rather low cross-section (15 mb at max), only

Cu activities of up to 700

have been reported through this reaction so far [ 37 ].…”

Section: Introductionmentioning

confidence: 99%

Cyclotron-Based Production of 67Cu for Radionuclide Theranostics via the 70Zn(p,α)67Cu Reaction

et al. 2023

View full text Add to dashboard Cite

Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although 61Cu and 64Cu are slowly being established as diagnostic radionuclides for PET, the availability of the therapeutic counterpart 67Cu plays a key role for further radiopharmaceutical development in the future. Until now, the 67Cu shortage has not been solved; however, different production routes are being explored. This project aims at the production of no-carrier-added 67Cu with high radionuclidic purity with a medical 30MeV compact cyclotron via the 70Zn(p,α)67Cu reaction. With this purpose, proton irradiation of electrodeposited 70Zn targets was performed followed by two-step radiochemical separation based on solid-phase extraction. Activities of up to 600MBq 67Cu at end of bombardment, with radionuclidic purities over 99.5% and apparent molar activities of up to 80MBq/nmol, were quantified.

show abstract

“…Radioconjugates for Targeted PET, PET/MR, and PET/NIRF Imaging of PCa NP-based radioconjugates for PET and PET/MR imaging of PCa have been focused on five positron-emitting radionuclides: 64 Cu, 68 Ga, 18 F, 124 I, and 89 Zr. Among them, 64 Cu was the most frequently used for radiolabelling of NPs due to its attractive nuclear properties [85][86][87]. The characteristics of 64 Cu and other radionuclides are presented in Table 2.…”

Section: Nanoparticle-basedmentioning

confidence: 99%

Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer

2023

View full text Add to dashboard Cite

Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death by cancer. Although most patients initially benefit from therapy, many of them will progress to metastatic castration-resistant prostate cancer, which still remains incurable. The significant mortality and morbidity rate associated with the progression of the disease results mainly from a lack of specific and sensitive prostate cancer screening systems, identification of the disease at mature stages, and failure of anticancer therapy. To overcome the limitations of conventional imaging and therapeutic strategies for prostate cancer, various types of nanoparticles have been designed and synthesized to selectively target prostate cancer cells without causing toxic side effects to healthy organs. The purpose of this review is to briefly discuss the selection criteria of suitable nanoparticles, ligands, radionuclides, and radiolabelling strategies for the development of nanoparticle-based radioconjugates for targeted imaging and therapy of prostate cancer and to evaluate progress in the field, focusing attention on their design, specificity, and potential for detection and/or therapy.

show abstract

Theragnostic 64Cu/67Cu Radioisotopes Production With RFT-30 Cyclotron

Cited by 8 publications

References 28 publications

Production of Medical Radionuclides in the Center for Radiopharmaceutical Tumor Research—A Status Report

Production of Medical Radionuclides in the Center for Radiopharmaceutical Tumor Research—A Status Report

Cyclotron-Based Production of 67Cu for Radionuclide Theranostics via the 70Zn(p,α)67Cu Reaction

Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer

Contact Info

Product

Resources

About